Lymphoid associated antigen expression in new cases of Acute Myeloid Leukemia

Jha, Runa; Grover, Geetanjali; Bose, Parveen

doi:10.3126/jpn.v3i6.8999

Cited by 9 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…whether included asynchronous antigens expression in addition to lymphoid associated antigens expression in AML cases 17 . Our figure of lymphoid antigens expression in AML (41.7%) is consistent with a previous study from Iraq (42%) 11 and approaching previous figures of 34.2% from Brazilm 18 , and 35% from India 19 ,but is lower than some other reported figures (47% -67.5%) [20][21][22] . CD56 was the most frequent lymphoid associated antigens expressed in our AML cases (13%).…”

Section: Discussionsupporting

confidence: 92%

Immunological Profile of Acute Myeloid Leukemia in Kurdistan Iraq

Salim¹

2018

DMJ

View full text Add to dashboard Cite

Background: Immunophenotyping has become crucial in the diagnosis and classification of acute leukemias and identification of its aberrant phenotypes. This study aimed to evaluate the patterns in AML cases presented to the flowcytometry unit at the Sulaimani Public Health Laboratory, Kurdistan, Iraq,and to determine the frequency of aberrant expression of lymphoid associated antigen. Subject and Methods: For the above purposes, 108 cases of acute myeloid leukemia (AML) were evaluated morphologically,and by flowcytometry with a panel of 22 antibodies. Furthermore, any aberrant expression of lymphoid associated antigens was reported. Results: The morphological AML subtyping revealed that 29.6% of AML cases were M2, while M1 (36.1%) was the predominant subtype by immunophenotyping using WHO 2008 classification. CD117, CD45, CD13 and CD33 were the most frequently expressed markers (99.1%, 92.6%, 92.6% and 85.2% respectively). Forty-five patients (41.7%) expressed lymphoid associated antigens (nTdT, CD19, CD79a, CD10, CD4, CD56 and CD9) that was demonstrated in all AML subtypesexcept M6.CD56 was the most frequent(13%),followed by CD9 (12%), CD4 (8.3%), and CD19 (7.4%).CD79a, nTdT and CD10 were less frequent, present in <5% of cases each. Conclusions: Immunophenotyping is an essential supplement to morphology in AML, whether for confirmation or accurate subtyping. Furthermore, more than 40% of cases show aberrant lymphoid antigen expression. The latter may serve as an important tool in future studies on minimal residual disease evaluation.

show abstract

Section: Discussionsupporting

confidence: 92%

Immunological Profile of Acute Myeloid Leukemia in Kurdistan Iraq

Salim¹

2018

DMJ

View full text Add to dashboard Cite

show abstract

“…The frequency of aberrant expression in AML in our study was 19.9% and this is in accordance to the results of some studies in which the aberrant expression ranged from 11.1% to 26.4% of AML cases (1,16,27,36,49). Many other studies reported higher frequency of aberrant expression among their AML patients between 30% -67.5% (13, 18,30,41,[50][51][52][53][54][55]. This variation in frequency of aberrant phenotypes in AML among different studies may be depending upon the markers studied, sample size or criteria of aberrancy used.…”

Section: Aberrant Expression In Aml Patientssupporting

confidence: 91%

Expression of aberrant markers in acute leukemia at South Egypt Cancer Institute: A retrospective study

2021

SECI Oncology Journal

View full text Add to dashboard Cite

Background: Aberrant phenotypes in acute leukemia (AL) have variable frequency and their prognostic relevance is controversial and dissimilar results have been reported by different groups. Objectives: To determine frequency of aberrant marker expression in acute leukemia at South Egypt Cancer Institute (SECI) and to relate these expression with patient outcome and cytogenetic abnormality. Patients and Methods: A retrospective study was conducted at SECI over a period of ten years. Total 1134 AL patients of both genders and all age groups were included in the study, of them 458 were diagnosed as acute myeloid leukemia (AML), 494 were diagnosed as B-acute lymphoblastic leukemia (B-ALL), 157 were diagnosed as T-ALL and 25 were diagnosed as biphenotypic AL (BAL). Results: Aberrant phenotypes were found in 91 (19.9%) cases of AML, 148 (30%) cases of

show abstract

“…CD7, a T-cell antigen known to show aberrant expression was most commonly expressed in our study (26.4%) followed by CD19 (1.2%). The same trend was observed in most of the international studies where CD7 was most commonly expressed aberrant antigen followed by CD19 2,8,14,16,20. CD7 expression in AML is correlated with lower incidence of complete remission 2.…”

Section: Discussionsupporting

confidence: 79%

Immunophenotypic characterisation of morphologically diagnosed cases of Acute Myeloid Leukaemia (AML)

Basharat¹,

Khan²,

Din³

et al. 2019

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To determine immunophenotypic pattern in newly diagnosed cases of acute myeloid leukaemia by flow cytometry and its correlation with morphological findings. Methods: This study was conducted at Haematology (Pathology) department, Army Medical College, in collaboration with Immunology Department Armed Forces Institute of Pathology, Rawalpindi from 16 November 2016 to 16 November 2017. One hundred and six patients of both genders and all age groups diagnosed as acute myeloid leukaemia were included in the study. Demographic data was noted. Complete blood counts, bone marrow examination and cytochemical stains were carried out and evaluated microscopically for blast percentage and morphology. Immunophenotyping was performed by flow cytometry using standard panel on peripheral blood or bone marrow samples. The surface and cytoplasmic antigens of interest were analysed and correlated with morphological findings. Results: The most commonly expressed antigens were CD13, CD33, CD45 and HLA-DR. Almost all blasts expressed CD45 with no remarkable difference among the subtypes of AML. The mean positivity for CD13 among all AML subtypes was 57% and for CD33 was 67%. Aberrant expression of CD7 and CD19 were expressed in 26.4% and 1.1% of all cases respectively. There was concordance rate of 90% between morphology and FCM in our study. Conclusion: Flow cytometric analysis of acute leukaemia done by a combination of patterns and intensity of antigen expression improves diagnostic yield in AML. CD13, CD33 and CD45 are the most frequently expressed antigens in AML. Our findings suggest a 90% concordance between morphology and flow cytometry. It is pertinent to conclude that flow cytometry results interpreted with morphology are complementary. How to cite this:Basharat M, Khan SA, Nasir ud Din, Ahmed D. Immunophenotypic characterisation of morphologically diagnosed cases of Acute Myeloid Leukaemia (AML). Pak J Med Sci. 2019;35(2):---------. doi: https://doi.org/10.12669/pjms.35.2.614 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Lymphoid associated antigen expression in new cases of Acute Myeloid Leukemia

Cited by 9 publications

References 17 publications

Immunological Profile of Acute Myeloid Leukemia in Kurdistan Iraq

Immunological Profile of Acute Myeloid Leukemia in Kurdistan Iraq

Expression of aberrant markers in acute leukemia at South Egypt Cancer Institute: A retrospective study

Immunophenotypic characterisation of morphologically diagnosed cases of Acute Myeloid Leukaemia (AML)

Contact Info

Product

Resources

About